Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies-Analysis of the WHO Pharmacovigilance Database.

Vincent RouleJoachim AlexandreAdrien LemaitreBasile ChrétienMarion SassierSophie FedrizziFarzin BeyguiCharles Dolladille

Published in: Cardiovascular drugs and therapy (2023)

Rhabdomyolysis reporting was increased when ticagrelor -but not other antiplatelet agents- was notified with the most prescribed statins in practice. This finding needs to be considered by physicians especially in high-risk patients.

Keyphrases

acute kidney injury
adverse drug
primary care
end stage renal disease
cardiovascular disease
chronic kidney disease
ejection fraction
acute coronary syndrome
newly diagnosed
healthcare
prognostic factors
quality improvement
patient reported outcomes